European Archives - Page 579 of 1006 - European Medical Journal

Connecting the Dots Between Skin and Allergy

Allergies represent a significant, rising health concern. Recent figures indicate that 150 million Europeans experience chronic allergic disease…

Positive Outcomes from Minimum Alcohol Pricing in Scotland

MINIMUM unit pricing (MUP) was first introduced in Scotland in 2018, raising the price per unit of alcohol to 50p. Now, experts…

Phage Therapy Shows Potential in Treating Alcoholic Liver Disease

BACTERIOPHAGES have been used to successfully treat alcoholic liver disease in mice in a recent study…

The News is all Good about Hepatitis C

I should not be alive to write this. It took a medical miracle, the world’s first ever cure for a virus, and some close timing. It also took me pushing…

Prostate Cancer Risk Lowered by Active Lifestyle

PHYSICAL activity could lower the risk of prostate cancer by as much as 51%. For men in the UK, prostate cancer…

Anthrax Combined with Growth Factor Kills Bladder Cancer Cells

ANTHRAX toxin combined with a growth factor has been found to be effective in treating bladder cancer…

EMJ Dermatology 7 [Suppl 10] 2019

IL-23 came under the spotlight during this year’s European Academy of Dermatology and Venereology (EADV) Congress in Madrid, Spain, as the subject…

IL-23 Inhibition: From Pathophysiological Jungle to Clinical Clearance

The symposium “IL-23 Inhibition: From Pathophysiological Jungle to Clinical Clearance” took place during the 2019 annual European Academy of Dermatology…

Latest Highlights from Guselkumab in Psoriasis from EADV 2019

Guselkumab was the first monoclonal antibody targeting the p19 subunit of IL-23 (IL-23p19) to be approved for the treatment of psoriasis.

Management of Moderate-to-Severe Atopic Dermatitis in the Era of Targeted Treatments

Prof Augustin opened the symposium by underlining how the management of patients with moderate-to-severe atopic dermatitis (AD) has become more dynamic…